Glenmark Pharmaceuticals Limited(IN:GLENMARK)
₹2,621.00-34.00 (-1.28%)
IN:GLENMARK
Glenmark Pharmaceuticals Limited earnings date
₹2,621.00
At close:-34.00 (-1.28%)
Want to see IN:GLENMARK full AI Analyst Report?
Glenmark Pharmaceuticals Limited (GLENMARK) Q2 2026 Earnings Report
5 Followers
IN:GLENMARK Q2 2026 EPS Results
- Actual EPS
- INR 21.62
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- INR 12.55
IN:GLENMARK Q2 2026 Revenue Results
- Actual Revenue
- INR 60.47B
- Expected Revenue
- INR 37.29B
- Beat/Miss
- Beat by +INR 23.17B
- YoY Revenue Growth
- +76.10%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 11/14/2025
- Time
- Before Open
- Conference Call
- Friday, November 14, 2025
IN:GLENMARK Upcoming Earnings
Glenmark Pharmaceuticals Limited's next earnings date is estimated for February 5, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
No earnings call summary is available for this earnings event.
IN:GLENMARK Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 05, 2027 | 2027 (Q3) | ―- | 14.28 | ― | ― |
| Nov 05, 2026 | 2027 (Q2) | 15.609.34 | 21.62 | -56.80% (-12.28) | |
| Jul 31, 2026 | 2027 (Q1) | 17.3017.11 | 1.66 | 930.72% (+15.45) | |
| May 29, 2026 | 2026 (Q4) | 18.2010.68 | 8.75 | 22.06% (+1.93) | |
| Jan 30, 2026 | 2026 (Q3) | 18.7014.28 | 12.3 | 16.10% (+1.98) | |
| Nov 14, 2025 | 2026 (Q2) | ―21.62 | 12.55 | 72.27% (+9.07) | |
| Aug 14, 2025 | 2026 (Q1) | 12.901.66 | 12.06 | -86.24% (-10.40) | |
| May 23, 2025 | 2025 (Q4) | 12.108.75 | -44.04 | 119.87% (+52.79) | |
| Feb 14, 2025 | 2025 (Q3) | 14.0512.30 | -12.5 | 198.40% (+24.80) | |
| Nov 14, 2024 | 2025 (Q2) | 14.7012.55 | 6.9 | 81.88% (+5.65) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

